Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Study sponsor: Corcept Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.